Twist Bioscience (NASDAQ:TWST) Trading Down 4.5% – What’s Next?

Twist Bioscience Co. (NASDAQ:TWST)’s share price fell 4.5% on Thursday . The stock traded as low as $49.14 and last traded at $49.98. 52,931 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 646,642 shares. The stock had previously closed at $52.34.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TWST shares. TD Cowen reaffirmed a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Scotiabank upped their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Trading Up 1.4 %

The company has a 50 day moving average of $47.41 and a 200-day moving average of $46.43.

Insider Transactions at Twist Bioscience

In related news, insider Dennis Cho sold 659 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now directly owns 94,481 shares of the company’s stock, valued at $3,926,630.36. The trade was a 0.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Adam Laponis sold 4,160 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $185,536.00. Following the completion of the sale, the chief financial officer now directly owns 89,237 shares in the company, valued at $3,979,970.20. This represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 87,379 shares of company stock valued at $4,026,346. 3.01% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

A number of large investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience in the third quarter worth approximately $34,000. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter. Finally, KBC Group NV increased its holdings in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.